Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of α-synuclein and β-amyloid and protect against amyloid-induced toxicity

Saviana Di Giovanni, Simona Eleuteri, Katerina E. Paleologou, Guowei Yin, Markus Zweckstetter, Pierre Alain Carrupt, Hilal A. Lashuel

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Parkinson disease (PD) is the second most common neurodegenerative disorder after Alzheimer disease (AD). There is considerable consensus that the increased production and/or aggregation of α-synuclein (α-syn) plays a central role in the pathogenesis of PD and related synucleinopathies. Current therapeutic strategies for treating PD offer mainly transient symptomatic relief and aim at the restitution of dopamine levels to counterbalance the loss of dopaminergic neurons. Therefore, the identification and development of drug-like molecules that block α-synuclein aggregation and prevent the loss of dopaminergic neurons are desperately needed to treat or slow the progression of PD. Here, we show that entacapone and tolcapone are potent inhibitors of α-syn and β-amyloid (Aβ) oligomerization and fibrillogenesis, and they also protect against extracellular toxicity induced by the aggregation of both proteins. Comparison of the anti-aggregation properties of entacapone and tolcapone with the effect of five other catechol-containing compounds, dopamine, pyrogallol, gallic acid, caffeic acid, and quercetin on the oligomerization and fibrillization of α-syn and Aβ, demonstrate that the catechol moiety is essential for the antiamyloidogenic activity. Our findings present the first characterization of the anti-amyloidogenic properties of tolcapone and entacapone against both α-synuclein and Aβ42 and highlight the potential of this class of nitro-catechol compounds as antiamyloidogenic agents. Their inhibitory properties, mode of action, and structural properties suggest that they constitute promising lead compounds for further optimization.

Original languageEnglish
Pages (from-to)14941-14954
Number of pages14
JournalJournal of Biological Chemistry
Volume285
Issue number20
DOIs
Publication statusPublished - 14 May 2010
Externally publishedYes

Fingerprint

Synucleins
Amyloid
Parkinson Disease
Toxicity
Agglomeration
Dopaminergic Neurons
Oligomerization
Dopamine
Neurons
Nitro Compounds
Pyrogallol
Gallic Acid
Quercetin
Lead compounds
Neurodegenerative Diseases
Consensus
Alzheimer Disease
Structural properties
tolcapone
entacapone

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of α-synuclein and β-amyloid and protect against amyloid-induced toxicity. / Di Giovanni, Saviana; Eleuteri, Simona; Paleologou, Katerina E.; Yin, Guowei; Zweckstetter, Markus; Carrupt, Pierre Alain; Lashuel, Hilal A.

In: Journal of Biological Chemistry, Vol. 285, No. 20, 14.05.2010, p. 14941-14954.

Research output: Contribution to journalArticle

Di Giovanni, Saviana ; Eleuteri, Simona ; Paleologou, Katerina E. ; Yin, Guowei ; Zweckstetter, Markus ; Carrupt, Pierre Alain ; Lashuel, Hilal A. / Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of α-synuclein and β-amyloid and protect against amyloid-induced toxicity. In: Journal of Biological Chemistry. 2010 ; Vol. 285, No. 20. pp. 14941-14954.
@article{33386ab24c7b4936bb4bd98e806c63aa,
title = "Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of α-synuclein and β-amyloid and protect against amyloid-induced toxicity",
abstract = "Parkinson disease (PD) is the second most common neurodegenerative disorder after Alzheimer disease (AD). There is considerable consensus that the increased production and/or aggregation of α-synuclein (α-syn) plays a central role in the pathogenesis of PD and related synucleinopathies. Current therapeutic strategies for treating PD offer mainly transient symptomatic relief and aim at the restitution of dopamine levels to counterbalance the loss of dopaminergic neurons. Therefore, the identification and development of drug-like molecules that block α-synuclein aggregation and prevent the loss of dopaminergic neurons are desperately needed to treat or slow the progression of PD. Here, we show that entacapone and tolcapone are potent inhibitors of α-syn and β-amyloid (Aβ) oligomerization and fibrillogenesis, and they also protect against extracellular toxicity induced by the aggregation of both proteins. Comparison of the anti-aggregation properties of entacapone and tolcapone with the effect of five other catechol-containing compounds, dopamine, pyrogallol, gallic acid, caffeic acid, and quercetin on the oligomerization and fibrillization of α-syn and Aβ, demonstrate that the catechol moiety is essential for the antiamyloidogenic activity. Our findings present the first characterization of the anti-amyloidogenic properties of tolcapone and entacapone against both α-synuclein and Aβ42 and highlight the potential of this class of nitro-catechol compounds as antiamyloidogenic agents. Their inhibitory properties, mode of action, and structural properties suggest that they constitute promising lead compounds for further optimization.",
author = "{Di Giovanni}, Saviana and Simona Eleuteri and Paleologou, {Katerina E.} and Guowei Yin and Markus Zweckstetter and Carrupt, {Pierre Alain} and Lashuel, {Hilal A.}",
year = "2010",
month = "5",
day = "14",
doi = "10.1074/jbc.M109.080390",
language = "English",
volume = "285",
pages = "14941--14954",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "20",

}

TY - JOUR

T1 - Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of α-synuclein and β-amyloid and protect against amyloid-induced toxicity

AU - Di Giovanni, Saviana

AU - Eleuteri, Simona

AU - Paleologou, Katerina E.

AU - Yin, Guowei

AU - Zweckstetter, Markus

AU - Carrupt, Pierre Alain

AU - Lashuel, Hilal A.

PY - 2010/5/14

Y1 - 2010/5/14

N2 - Parkinson disease (PD) is the second most common neurodegenerative disorder after Alzheimer disease (AD). There is considerable consensus that the increased production and/or aggregation of α-synuclein (α-syn) plays a central role in the pathogenesis of PD and related synucleinopathies. Current therapeutic strategies for treating PD offer mainly transient symptomatic relief and aim at the restitution of dopamine levels to counterbalance the loss of dopaminergic neurons. Therefore, the identification and development of drug-like molecules that block α-synuclein aggregation and prevent the loss of dopaminergic neurons are desperately needed to treat or slow the progression of PD. Here, we show that entacapone and tolcapone are potent inhibitors of α-syn and β-amyloid (Aβ) oligomerization and fibrillogenesis, and they also protect against extracellular toxicity induced by the aggregation of both proteins. Comparison of the anti-aggregation properties of entacapone and tolcapone with the effect of five other catechol-containing compounds, dopamine, pyrogallol, gallic acid, caffeic acid, and quercetin on the oligomerization and fibrillization of α-syn and Aβ, demonstrate that the catechol moiety is essential for the antiamyloidogenic activity. Our findings present the first characterization of the anti-amyloidogenic properties of tolcapone and entacapone against both α-synuclein and Aβ42 and highlight the potential of this class of nitro-catechol compounds as antiamyloidogenic agents. Their inhibitory properties, mode of action, and structural properties suggest that they constitute promising lead compounds for further optimization.

AB - Parkinson disease (PD) is the second most common neurodegenerative disorder after Alzheimer disease (AD). There is considerable consensus that the increased production and/or aggregation of α-synuclein (α-syn) plays a central role in the pathogenesis of PD and related synucleinopathies. Current therapeutic strategies for treating PD offer mainly transient symptomatic relief and aim at the restitution of dopamine levels to counterbalance the loss of dopaminergic neurons. Therefore, the identification and development of drug-like molecules that block α-synuclein aggregation and prevent the loss of dopaminergic neurons are desperately needed to treat or slow the progression of PD. Here, we show that entacapone and tolcapone are potent inhibitors of α-syn and β-amyloid (Aβ) oligomerization and fibrillogenesis, and they also protect against extracellular toxicity induced by the aggregation of both proteins. Comparison of the anti-aggregation properties of entacapone and tolcapone with the effect of five other catechol-containing compounds, dopamine, pyrogallol, gallic acid, caffeic acid, and quercetin on the oligomerization and fibrillization of α-syn and Aβ, demonstrate that the catechol moiety is essential for the antiamyloidogenic activity. Our findings present the first characterization of the anti-amyloidogenic properties of tolcapone and entacapone against both α-synuclein and Aβ42 and highlight the potential of this class of nitro-catechol compounds as antiamyloidogenic agents. Their inhibitory properties, mode of action, and structural properties suggest that they constitute promising lead compounds for further optimization.

UR - http://www.scopus.com/inward/record.url?scp=77952087072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952087072&partnerID=8YFLogxK

U2 - 10.1074/jbc.M109.080390

DO - 10.1074/jbc.M109.080390

M3 - Article

C2 - 20150427

AN - SCOPUS:77952087072

VL - 285

SP - 14941

EP - 14954

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 20

ER -